phase readout
saveNCT06869785: Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
ACTIVE_NOT_RECRUITINGupdated 5d ago
community read0 votes
Sponsor: Novartis Pharmaceuticals. Phase: PHASE3. Conditions: Relapsing Multiple Sclerosis (RMS)
view source ↗
comments(0)
5-min edit window · permanent after that